Their new, 5000 sqft, purpose-built facility makes Rapid Novor the largest privately funded proteomics mass spectrometry lab in Ontario.
KITCHENER, ONTARIO (PRWEB) OCTOBER 02, 2019
Rapid Novor, Inc., the world’s leader in antibody protein sequencing using mass spectrometry, is pleased to announce that it has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. Now home to four proteomics-grade mass spectrometers among other analytical instruments, the new facility demonstrates the company’s continuous commitment to quality research and service offerings.
The new facility is located at Catalyst 137, an innovation hub hosting the best and the brightest high growth companies in the Kitchener-Waterloo region. The company’s new space includes a mass spectrometry lab, a biochemistry lab and a large open office area, where people from all disciplines collaborate, communicate, learn and innovate without barriers.
“Moving into the new facility is a significant milestone for the company. The new facility provides the space and infrastructure we need for our next phase of growth,” says Mingjie Xie, co-founder and CEO. “When designing the new space, we always kept one thing in mind, that our new home must continue to foster and facilitate open communication, collaboration and innovation. This is part of our core value.”
“We have tripled the lab space in our new facility,” says Dr. Bin Ma, co-founder and Chief Scientist. “The larger space will allow us to host more equipment and have a larger team conducting research experiments at the same time. This, in turn, will provide higher throughput for both our services and innovation.”
About Rapid Novor, Inc.
Rapid Novor, Inc. is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing access to the producing cell line. As a University of Waterloo spin-off, the company continues to build its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAb™ antibody protein sequencing service has allowed for the accurate sequencing of any given antibody proteins on a routine basis in high throughput manner. The company’s WILD™ service is the first commercially available service that can accurately distinguish the isobaric Isoleucine and Leucine using mass spectrometry. For more information, please visit https://www.rapidnovor.com. Follow the company on Twitter @rapidnovor and LinkedIn https://www.linkedin.com/company/rapid-novor-inc/.
“The new facility provides the space and infrastructure we need for our next phase of growth.” says Mingjie Xie, co-founder and CEO.